

DATA REPORT

Open Access

# Lack of association between *PER3* variable number tandem repeat and circadian rhythm sleep–wake disorders

Akiko Hida<sup>1</sup>, Shingo Kitamura<sup>1</sup>, Hiroshi Kadotani<sup>2</sup>, Makoto Uchiyama<sup>3</sup>, Takashi Ebisawa<sup>4</sup>, Yuichi Inoue<sup>5,6</sup>, Yuichi Kamei<sup>7</sup> and Kazuo Mishima<sup>1</sup>

## Abstract

Circadian rhythm sleep–wake disorders (CRSWDs) are characterized by disturbed sleep–wake patterns. We genotyped a *PER3* variable number tandem repeat (VNTR) in 248 CRSWD individuals and 925 controls and found no significant association between the VNTR and CRSWDs or morningness–eveningness (diurnal) preferences in the Japanese population. Although the VNTR has been associated with circadian and sleep phenotypes in some other populations, the polymorphism may not be a universal genetic marker.

Circadian clocks regulate daily behavioral and physiological rhythms, such as sleep and wakefulness<sup>1</sup>. The molecular mechanism of the circadian clock system involves transcription–translation–negative feedback loops of multiple clock genes, including *ARNTL* (also known as *BMAL1*), *Casein Kinase I (CKI)*, *CLOCK*, *CRY*, and *PER*. The *BMAL1* and *CLOCK* proteins form heterodimers and activate transcription of *CRY* and *PER*. The *CRY* and *PER* proteins gradually accumulate in the cytoplasm, and *CRY*, *PER*, and *CKI* proteins form complexes that translocate to the nucleus. These protein complexes interact with *BMAL1*–*CLOCK* heterodimers, thereby inhibiting transcription of the *CRY* and *PER* genes<sup>2</sup>. Circadian rhythm sleep–wake disorders (CRSWDs) are defined by persistent or recurrent disturbed sleep–wake patterns and are thought to result from impairment of the circadian clock system<sup>3</sup>. CRSWDs consist of several subtypes, including delayed sleep–wake phase disorder (DSWPD) and non-24-hour sleep–wake

rhythm disorder (N24SWD). DSWPD is characterized by significantly delayed sleep timing, while N24SWD is characterized by sleep timing that progressively delays each day in normal real-life settings. Additionally, circadian and sleep characteristics vary greatly among individuals<sup>4</sup>. A number of studies have shown that genetic factors significantly contribute to individual differences in daily activity/sleep time, known as morningness–eveningness preferences (or diurnal preferences), and sleep phenotypes<sup>5</sup>. The *PER3* gene has a variable number tandem repeat (VNTR) consisting of either 4 or 5 repeated 54-bp sequences encoding 18 amino acids<sup>6</sup>. The 4-repeat allele of the VNTR has been associated with extreme evening preference and DSWPD<sup>6,7</sup>, while the 5-repeat allele of the VNTR has been associated with extreme morning preference and greater sleep propensity<sup>7,8</sup>. However, the frequency of the VNTR polymorphism differs among various populations<sup>9,10</sup> and has not been examined in a large Japanese cohort of CRSWD patients and controls. In this study, we genotyped the *PER3* VNTR polymorphism in 180 individuals with DSWPD, 68 individuals with N24SWD, and 925 controls and tested the VNTR polymorphism for associations with CRSWD phenotypes in the patient group and with diurnal preferences in the control group.

Correspondence: Akiko Hida ([hida@ncnp.go.jp](mailto:hida@ncnp.go.jp))

<sup>1</sup>Department of Sleep–Wake Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo 187-8553, Japan

<sup>2</sup>Department of Sleep and Behavioral Sciences, Shiga University of Medical Science, Shiga 520-2192, Japan

Full list of author information is available at the end of the article.

© The Author(s) 2018



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

**Table 1 Genotype and allele frequency of the *PER3* VNTR in the control, DSWPD and N24SWD groups**

Group	N	Genotype [N (%)]			Allele [N (%)]		$\chi^2$	P
		4/4	4/5	5/5	4	5		
Control	925	635 (68.65)	260 (28.11)	30 (3.24)	1530 (82.70)	320 (17.30)	3.0608	0.2165
DSWPD	180	115 (63.89)	56 (31.11)	9 (5.00)	286 (79.44)	74 (20.56)		
N24SWD	68	48 (70.59)	20 (29.41)	0 (0.00)	116 (85.29)	20 (14.71)		

N number, 4/4 homozygosity for the 4-repeat allele, 4/5 heterozygosity, 5/5 homozygosity for the 5-repeat allele, P P value for the difference in allele frequency among the control, DSWPD, and N24SWD groups

**Table 2 Genotype and allele frequency of the *PER3* VNTR in the morning, intermediate, and evening types**

Type	N	Genotype [N (%)]			Allele [N (%)]		$\chi^2$	P
		4/4	4/5	5/5	4	5		
Morning	245	160 (65.31)	81 (33.06)	4 (1.63)	401 (81.84)	89 (18.16)	3.1694	0.205
Intermediate	594	421 (70.88)	152 (25.59)	21 (3.54)	994 (83.67)	194 (16.33)		
Evening	86	54 (62.79)	27 (31.40)	5 (5.81)	135 (78.49)	37 (21.51)		

N number, 4/4 homozygosity for the 4-repeat allele, 4/5 heterozygosity, 5/5 homozygosity for the 5-repeat allele, P P value for the difference in allele frequency among the morning, intermediate, and evening types

The study population consisted of 180 DSWPD individuals (109 men and 71 women; mean  $\pm$  SD age: 26.71  $\pm$  9.29 years), 68 N24SWD individuals (48 men and 20 women; mean  $\pm$  SD age: 26.63  $\pm$  9.74 years), and 925 controls (274 men and 651 women; mean  $\pm$  SD age: 36.45  $\pm$  12.10 years). Patient subjects and controls had been examined in an earlier study of ours<sup>11</sup>. All participants were unrelated, sighted Japanese men and women who were recruited at medical and research institutes in Japan. None of the controls had a history of sleep disorders or psychosis. The DSWPD and N24SWD patients were diagnosed by trained psychiatrists according to the International Classification of Sleep Disorders, Third Edition (ICSD-III, 2014)<sup>12</sup>. Diurnal preferences were assessed by the Japanese version of the Horne-Östberg Morningness-Eveningness Questionnaire (MEQ)<sup>13</sup> in our previous study<sup>11</sup>. The 925 controls consisted of 245 morning types (79 men and 166 women; mean  $\pm$  SD age: 36.23  $\pm$  12.19 years), 594 intermediate types (163 men and 431 women; mean  $\pm$  SD age: 36.86  $\pm$  12.05 years), and 86 evening types (32 men and 54 women; mean  $\pm$  SD age: 37.60  $\pm$  10.69 years). The protocol was approved by the respective institutional ethical review boards. All subjects provided written informed consent. The present study was conducted according to the principles of the Declaration of Helsinki.

The 4- or 5-repeat allele of the *PER3* VNTR was assessed by polymerase chain reaction (PCR). The primers used to amplify the DNA fragments containing 4 or 5 repeated 54-bp sequences were as follows: 5'-CAAAATT TTATGACACTACCAGAATGGCTGAC-3', 5'-AACCT

TGTACTIONTCCACATCAGTGCCTGG-3'. The PCR reaction was carried out in a 10- $\mu$ l mixture containing AmpliTaq Gold 360 Master Mix and 360 GC Enhancer (Thermo Fisher Scientific, CA, USA), 1  $\mu$ M of each primer, and 10 ng of genomic DNA and run in the GeneAmp PCR System 9600 (Thermo Fisher Scientific, CA, USA). Amplification conditions were as follows: 1 cycle of 95  $^{\circ}$ C for 5 min, 35 cycles of 95  $^{\circ}$ C for 30 s, 60  $^{\circ}$ C for 30 s, 72  $^{\circ}$ C for 30 s, and 1 cycle of 72  $^{\circ}$ C for 7 min. The PCR fragments were subject to electrophoresis in a 3% agarose gel.

Table 1 shows the genotypic and allelic distribution of the *PER3* VNTR in controls, DSWPD individuals, and N24SWD individuals. Homozygosity for the 4-repeat allele *PER3*-(4/4) is the most common (63.89–70.59 %), and homozygosity for the 5-repeat allele *PER3*-(5/5) is the least common (0–5 %), with the 4-repeat allele having higher prevalence (79.44–85.29 %) than the 5-repeat allele (14.71–20.56 %) in the control, DSWPD, and N24SWD groups. The allele frequency of the *PER3* VNTR was compared among the three groups, and no significant difference was identified in the VNTR frequency ( $\chi^2 = 3.0608$ ,  $P = 0.2165$ ). The *PER3* VNTR was not associated with CRSWD phenotypes in our study samples. We then assessed the association of the *PER3* VNTR with diurnal preferences (Table 2). Similarly, *PER3*-(4/4) is the most common polymorphism (62.79–70.88 %), *PER3*-(5/5) is the least common polymorphism (1.63–5.81 %), and the 4-repeat allele is more prevalent (78.49–83.67 %) than the 5-repeat allele (16.33–21.51 %) in the morning-, intermediate-, and evening-type groups. The VNTR alleles did not differ among these three types ( $\chi^2 = 3.1694$ ,  $P =$

0.205). No significant association was identified between the *PER3* VNTR and diurnal preferences in our control samples. Age-adjusted MEQ scores were  $52.93 \pm 7.86$  (mean  $\pm$  SD) for *PER3*-(4/4),  $53.56 \pm 8.57$  for *PER3*-(4/5), and  $50.02 \pm 8.06$  for *PER3*-(5/5). There was no difference in age-adjusted MEQ scores among the three genotypes ( $F(2, 922) = 2.171$ ;  $P = 0.115$ ).

We found no significant association of the *PER3* VNTR with CRSWD phenotypes or diurnal preferences in our Japanese cohort. The frequency distribution of the *PER3* VNTR differs among African American, European American, Ghana Africans, Han Chinese, and Italian populations<sup>10,14</sup>. The data indicate that the associations between the VNTR and circadian and sleep phenotypes could differ among populations. Significant associations between the VNTR and diurnal preferences were found in the British populations<sup>7,15</sup> but not in the Han Chinese populations<sup>14</sup>. The *PER3* VNTR may not be an appropriate genetic marker for predicting circadian and sleep phenotypes in some populations, including the Japanese population. However, a number of studies indicate close links between the *PER3* gene and circadian rhythms and sleep homeostasis<sup>8,16,17</sup>. Polymorphisms in the *PER3* promoter are associated with DSWPD and these polymorphisms alter *PER3* expression levels<sup>18</sup>. Our previous study demonstrated that a missense polymorphism in the *PER3* coding region (rs228697) is associated with N24SWD and diurnal preferences<sup>11</sup>. Additionally, another group has recently identified the association of rs228697 with diurnal preferences<sup>19</sup>. Furthermore, the *PER3* protein with the rs228697 variant has been shown to be a strong repressor for CLOCK–BMAL1-induced transcription<sup>20</sup>. These findings suggest that the *PER3* gene could play an important role in the circadian clock system and sleep regulation.

In conclusion, our data show no significant association between the *PER3* VNTR and CRSWD phenotypes or diurnal preferences in our Japanese cohort. The results of our study imply that the *PER3* VNTR may not be a universal genetic marker for an individual's circadian and sleep phenotypes.

#### HGVD Database

The relevant data from this Data Report are hosted at the Human Genome Variation Database at <https://doi.org/10.6084/m9.figshare.hgv.2336> and <https://doi.org/10.6084/m9.figshare.hgv.2339>.

#### Acknowledgements

This study was supported by Grants-in-Aid for Scientific Research (#15K07580, #15K09817 and #16H05381) from the Japan Society for the Promotion of Science (JSPS), Intramural Research Grant (#26-2) for Neurological and Psychiatric Disorders from the National Center of Neurology and Psychiatry and a grant from the Takeda Research Foundation.

#### Author details

<sup>1</sup>Department of Sleep-Wake Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo 187-8553, Japan. <sup>2</sup>Department of Sleep and Behavioral Sciences, Shiga University of Medical Science, Shiga 520-2192, Japan. <sup>3</sup>Department of Psychiatry, Nihon University School of Medicine, Tokyo 173-8610, Japan. <sup>4</sup>Yokohama Clinic for Psychosomatic Medicine and Psychiatry, Medical Corporation Warakukai, Kanagawa 220-0004, Japan. <sup>5</sup>Department of Somnology, Tokyo Medical University, Tokyo 160-8402, Japan. <sup>6</sup>Yoyogi Sleep Disorder Center, Tokyo 151-0053, Japan. <sup>7</sup>Department of Laboratory Medicine, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan

#### Conflict of interest

A.H. has received research grants from the Japan Society for the Promotion of Science (JSPS) and Takeda Research Foundation. S.K. has received research grants from JSPS and the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT)/JSPS. H.K.'s laboratory has been supported by a donation from Fukuda Lifetech, Fukuda Life Tech Keiji, Tanaka Sleep Clinic, Akita Sleep Clinic, and Ai Ai Care to the Shiga University of Medical Science, and H.K. has received research grants from JSPS and MEXT/JSPS and Merck Sharp & Dohme Corporation/MSD. M.U. has received speaker's honoraria from Eisai and Takeda. T.E. declares no conflict of interest. Y.I. has received research support from Takeda, Astellas, Alfresa, Philips Respironics, MSD, Eisai, Otsuka, and Koike Medical and speaker's honorarium from Takeda, Astellas, Alfresa, Philips Respironics, MSD, Eisai, and Otsuka. Y.K. has received research support from the Japanese Ministry of Health, Labour and Welfare (MHLW) and speaker's honoraria from Eisai, MSD, and Kaken. K.M. has received research support from MHLW, speaker's honoraria from Eisai, MSD, and Takeda, and research grants from JSPS, Eisai, Nobelpharma, and Takeda.

#### Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 19 May 2018 Accepted: 27 May 2018

Published online: 12 July 2018

#### References

- Pittendrigh, C. S. Temporal organization: reflections of a Darwinian clock-watcher. *Annu. Rev. Physiol.* **55**, 16–54 (1993).
- Lowrey, P. L. & Takahashi, J. S. Genetics of the mammalian circadian system: Photoc entrainment, circadian pacemaker mechanisms, and posttranslational regulation. *Annu. Rev. Genet.* **34**, 533–62 (2000).
- Ebisawa, T. Analysis of the molecular pathophysiology of sleep disorders relevant to a disturbed biological clock. *Mol. Genet. Genomics* **288**, 185–93 (2013).
- Horne, J. A. & Ostberg, O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. *Int. J. Chronobiol.* **4**, 97–110 (1976).
- Barclay, N. L. & Gregory, A. M. Quantitative genetic research on sleep: a review of normal sleep, sleep disturbances and associated emotional, behavioural, and health-related difficulties. *Sleep Med. Rev.* **17**, 29–40 (2013).
- Ebisawa, T. et al. Association of structural polymorphisms in the human period3 gene with delayed sleep phase syndrome. *EMBO Rep.* **2**, 342–6 (2001).
- Archer, S. N. et al. A length polymorphism in the circadian clock gene *Per3* is linked to delayed sleep phase syndrome and extreme diurnal preference. *Sleep* **26**, 413–5 (2003).
- Groeger, J. A. et al. Early morning executive functioning during sleep deprivation is compromised by a PERIOD3 polymorphism. *Sleep* **31**, 1159–67 (2008).
- Nadkarni, N. A., Weale, M. E., von Schantz, M. & Thomas, M. G. Evolution of a length polymorphism in the human *PER3* gene, a component of the circadian system. *J. Biol. Rhythms* **20**, 490–9 (2005).
- Ciarleglio, C. M. et al. Genetic differences in human circadian clock genes among worldwide populations. *J. Biol. Rhythms* **23**, 330–40 (2008).

11. Hida, A. et al. Screening of clock gene polymorphisms demonstrates association of a PER3 polymorphism with morningness-eveningness preference and circadian rhythm sleep disorder. *Sci. Rep.* **4**, 6309 (2014).
12. American Academy of Sleep Medicine. *The International Classification of Sleep Disorders, Third Edition (ICSD-III)* (Darien, IL, 2014).
13. Ishihara, K., Saitoh, T., Inoue, Y. & Miyata, Y. Validity of the Japanese version of the Morningness-Eveningness Questionnaire. *Percept. Mot. Skills* **59**, 863–6 (1984).
14. An, H. et al. Chronotype and a PERIOD3 variable number tandem repeat polymorphism in Han Chinese pilots. *Int. J. Clin. Exp. Med.* **7**, 3770–6 (2014).
15. Jones, K. H. et al. Age-related change in the association between a polymorphism in the PER3 gene and preferred timing of sleep and waking activities. *J. Sleep Res.* **16**, 12–6 (2007).
16. Viola, A. U. et al. PER3 polymorphism predicts sleep structure and waking performance. *Curr. Biol.* **17**, 613–8 (2007).
17. Goel, N. Genetics of sleep timing, duration and homeostasis in humans. *Sleep Med. Clin.* **6**, 171–82 (2011).
18. Archer, S. N. et al. Polymorphism in the PER3 promoter associates with diurnal preference and delayed sleep phase disorder. *Sleep* **33**, 695–701 (2010).
19. Turco, M. et al. Diurnal preference, mood and the response to morning light in relation to polymorphisms in the human clock gene PER3. *Sci. Rep.* **7**, 6967 (2017).
20. Shi, S. Q. et al. Molecular analyses of circadian gene variants reveal sex-dependent links between depression and clocks. *Transl. Psychiatry* **6**, e748 (2016).